NCT02639026 2025-11-25
Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers
Abramson Cancer Center at Penn Medicine
Phase 1 Completed
Clinical Trials
9 trialsNCT04107168 2023-02-16
Microbiome Immunotherapy Toxicity and Response Evaluation
Cambridge University Hospitals NHS Foundation Trust
Unknown
NCT02643303 2022-12-02
A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers
Ludwig Institute for Cancer Research
Phase 1/2 Completed
NCT04223648 2021-11-22
Programmed Cell Death 1 + Selected Cell Therapy With Durvalumab (MEDI4736) and Tremelimumab in Metastatic Melanoma
Yale University
Phase EARLY_PHASE1 Withdrawn
NCT00471887 2020-10-26
Ticilimumab (CP-675,206) in Treating Patients With Stage IIIC or Stage IV Melanoma
Jonsson Comprehensive Cancer Center
Phase 2 Completed
NCT01103635 2020-04-07
Tremelimumab and CP-870,893 in Patients With Metastatic Melanoma
Abramson Cancer Center at Penn Medicine
Phase 1 Completed
NCT04274816 2020-02-18
Intradermal Injection of Anti-CTLA-4 in Patients With Stage I/II Melanoma
Amsterdam UMC, location VUmc
Phase 1 Completed
NCT00610857 2017-06-22
Safety and Efficacy of Combination HDI and Anti-CTLA4 for Recurrent Inoperable Stage III or Stage IV Melanoma
University of Pittsburgh
Phase 2 Completed
NCT00897312 2016-04-25
Effect of Biological Therapy on Biomarkers in Patients With Untreated Hepatitis C, Metastatic Melanoma, or Crohn Disease
Vanderbilt-Ingram Cancer Center
Terminated